Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 2/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18202442 | 0.91 | POLB (0.51) | TSHRALDH1A1POLBGAARAB9A | |
| SCHEMBL807262 | 0.88 | TSHR (0.50) | TSHRTDP1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL27515952 | 0.87 | POLB (0.54) | TSHRTDP1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL19364381 | 0.87 | ITGB1 (0.53) | ALDH1A1MAPK1 | |
| SCHEMBL19088526 | 0.86 | TSHR (0.48) | TSHRTDP1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL9488064 | 0.86 | TACR1 (0.61) | TSHRALDH1A1POLBBIRC2GAA | |
| SCHEMBL9486892 | 0.86 | TACR1 (0.61) | TSHRALDH1A1POLBBIRC2GAA | |
| SCHEMBL21578800 | 0.86 | TSHR (0.48) | TSHRTDP1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL9487238 | 0.85 | POLB (0.53) | TSHRALDH1A1POLBBIRC2GAA | |
| SCHEMBL9487233 | 0.85 | POLB (0.53) | TSHRALDH1A1POLBBIRC2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2007002808-A1 | ANTI-NONMELANOMA CARCINOMA COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | TSHR 541/4885TDP1 1536/4885L3MBTL1 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.